Cigna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied for failing step therapy by Cigna?

Q: How long do I have to appeal a Cigna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

T2DM diagnosis required (CNF-749); HbA1c ≥6.5% consistent with ADA.

Source policy: Cigna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Cigna angle on Tirzepatide

# Cigna Step-Therapy Denial for Tirzepatide — Reason-Anchored Appeal Strategy

Cigna's step-therapy denial on tirzepatide (Mounjaro for T2DM, Zepbound for chronic weight management) is administered through Express Scripts/Evernorth, Cigna's wholly-owned PBM, under Coverage Policy IP0556 (Mounjaro) and Coverage Policy IP0578 (Zepbound). The step protocol typically requires documented trial and failure of metformin plus a second-line agent — usually a sulfonylurea, SGLT2 inhibitor, or a preferred GLP-1 such as semaglutide (Ozempic) — before tirzepatide is authorized. The denial letter cites coverage criterion CNF-749 confirming T2DM diagnosis and an HbA1c ≥6.5% consistent with ADA Standards of Care.

The procedural mechanic here is critical. Step-therapy in an ERISA-governed commercial plan is an NQTL (non-quantitative treatment limitation) under 29 CFR §2590.712 and is independently regulated by 29 USC §1185d, which requires plans to honor a step-therapy override when (a) the required drug is contraindicated, (b) the patient previously tried and failed it on any plan, (c) the patient is stable on the requested drug, or (d) the required drug is expected to be ineffective. Cigna's own Coverage Policy IP0556 explicitly incorporates these override pathways, but the burden falls on the prescriber to invoke them by name with chart-documented evidence.

The first appeal must go through the Evernorth/Express Scripts coverage review portal (not the Cigna medical portal — this is a pharmacy benefit). Submit an eviCore/Express Scripts step-therapy exception form citing the specific override prong. If the patient previously failed semaglutide due to GI intolerance, attach the pharmacy fill history and clinic note documenting the AE — Evernorth's reviewers reject vague "intolerance" language without dated documentation. If the patient was stable on tirzepatide under a prior plan (common in employer transitions), invoke 45 CFR §156.122 continuity-of-care and the ACA non-discrimination protections.

For self-funded ERISA plans, demand the full administrative record under 29 CFR §2560.503-1(h)(2)(iii) — including the internal clinical rationale and the version of IP0556 in force on the denial date. Cigna routinely updates these policies quarterly, and reviewers sometimes apply a newer/stricter version retroactively. Pinto v. Aetna (10th Cir. 2014) confirms the insurer bears the burden of justifying coverage restrictions on appeal; a bare "step not met" denial without policy citation is reversible.

If Evernorth upholds, escalate to Cigna's Level 2 internal appeal, then to external IRO review under state law (or federal IRO if self-funded). For fully-insured plans, parallel-file a state DOI complaint — Texas, California, and New York DOIs have aggressively enforced step-therapy override statutes against Cigna in 2024–2025.

Tactical tip: Attach a one-page "override prong checklist" mapping each of the four 29 USC §1185d prongs to specific chart entries with dates and ICD-10/J-codes. Evernorth reviewers approve checklisted submissions at materially higher rates than narrative-only letters.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other insurers on Tirzepatide

Other denial reasons for Cigna Tirzepatide

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.